Capricor Therapeutics, Inc. Stock

$7.64

32.98%

Nasdaq, Jul 11, 10:16 pm CET

ISIN

US14070B1017

Symbol

CAPR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Capricor Therapeutics, Inc. Stock price

$7.64

+3.56 87.25% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

-3.76 32.98%

ISIN

US14070B1017

Symbol

CAPR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$349.2m

Enterprise Value

$207.8m

Net debt

positive

Cash

$144.8m

Shares outstanding

45.7m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

20.1 | 2.8

EV/Sales

12.0 | 1.7

EV/FCF

negative

P/B

2.7

Financial Health

Equity Ratio

85.3%

Return on Equity

-27.8%

ROCE

-43.6%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$17.4m | $123.4m

EBITDA

$-56.9m | $-49.4m

EBIT

$-57.3m | $-30.0m

Net Income

$-55.1m | $-44.3m

Free Cash Flow

$-47.2m

Growth (TTM | estimate)

Revenue

-36.0% | 453.9%

EBITDA

-127.6% | -172.9%

EBIT

-119.0% | -53.9%

Net Income

-126.4% | -9.4%

Free Cash Flow

-41.5%

EPS

$-1.2

FCF per Share

$-1.0

Short interest

25.4%

Employees

160

Rev per Employee

$140.0k

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Capricor Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

??

16 Analysts have issued a Capricor Therapeutics, Inc. forecast:

15x Buy

94%

More details on Analyst Estimates Including Price Targets

16 Analysts have issued a Capricor Therapeutics, Inc. forecast:

Buy

94%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Capricor Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	17 17	36% 36% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	17 17	25% 25% 96%
- Research and Development Expense	58 58	44% 44% 332%
EBITDA	-57 -57	128% 128% -328%
- Depreciation and Amortization	0.41 0.41	65% 65% 2%
EBIT (Operating Income) EBIT	-57 -57	119% 119% -330%
Net Profit	-55 -55	126% 126% -317%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Capricor Therapeutics, Inc. Stock News

Neutral

Business Wire

●

2 days ago

Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura

OAKLAND, Calif.--(BUSINESS WIRE)---- $CAPR #CAPR--Shares of Capricor Therapeutics, Inc. plunged over 30% in intraday trading on Friday, July 11, 2025, after the U.S. Food and Drug Administration rejected the company's Biologics License Application for its lead cell therapy candidate, Deramiocel, claiming that the application “does not meet the statutory requirement for substantial evidence of e...

Neutral

GlobeNewsWire

●

2 days ago

INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. (CAPR) Announced by Holzer & Holzer, LLC

ATLANTA, July 11, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) complied with federal securities laws. On July 11, 2025, Capricor announced that it had received a Complete Response Letter (“CRL”) from the FDA regarding its Biologics License Application (“BLA”) for Deramiocel. Following this news, t...

Negative

Proactive Investors

●

2 days ago

Capricor Therapeutics shares tumble as FDA rejects Duchenne muscular dystrophy drug application

Capricor Therapeutics (NASDAQ:CAPR) shares plummeted more than 26% after it reported the US Food and Drug Administration (FDA) has not approved its Biologics License Application for deramiocel, the company's lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). In a Complete Response Letter to Capricor, the FDA stated that the applica...

More Capricor Therapeutics, Inc. News

Company Profile

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.

Head office	United States
CEO	Linda Marbán
Employees	160
Founded	1996
Website	capricor.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now